Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVIG · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IVIG | EXPERIMENTAL | Intravenous Immune Globulin |
| Name | Type | Description |
|---|---|---|
| IVIG | BIOLOGICAL | Intravenous Immune Globulin |
Inclusion Criteria: 1. Outpatients with SCA diagnosed by a movement disorder specialist. 2. Age 10 years to 80 years. 3. Able to ambulate with or without assistance for 30 feet. 4. Women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy tes...
IVIG is being studied as a treatment for spinocerebellar ataxia, a neurological condition. It is an investigational therapy in clinical development, and it has not been approved for this use. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in patients with this condition.
IVIG is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker symbol BAX. The company is conducting clinical research to evaluate the drug's potential in treating spinocerebellar ataxia.
IVIG is in Phase 2 clinical development for spinocerebellar ataxia. A Phase 2 trial has been completed, and the drug remains investigational. It is not approved by regulatory authorities for this indication.
IVIG has been studied in one clinical trial, identified as NCT01350440, titled 'Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia.' This Phase 2 trial was completed in the United States and enrolled 5 participants.
Yes, IVIG is a monoclonal antibody. It is being evaluated as a therapeutic option for spinocerebellar ataxia, a neurological disorder. The drug is in clinical development and has undergone a Phase 2 trial to assess its safety and efficacy.